A5078973225- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Nausea and vomiting management
- Anesthesia and Pain Management
- Chemotherapy-related skin toxicity
- PI3K/AKT/mTOR signaling in cancer
- Innovations in Medical Education
- Cancer Immunotherapy and Biomarkers
- Diversity and Career in Medicine
- Cutaneous lymphoproliferative disorders research
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Medical Education and Admissions
- Cancer Genomics and Diagnostics
- Immunodeficiency and Autoimmune Disorders
- Neutropenia and Cancer Infections
- Pancreatic and Hepatic Oncology Research
- Intraperitoneal and Appendiceal Malignancies
- T-cell and Retrovirus Studies
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2014-2023
The Ohio State University
2014-2023
College of St. Scholastica
2023
An aggressive lymphoma in a patient with chronic lymphocytic leukaemia (CLL), known as Richter syndrome (RS), has poor prognosis and is an important unmet clinical need (Richter, 1928; Parikh et al, 2014). Standard treatment chemoimmunotherapy unsuitable for many patients who are unfit these intensive regimens or have disease features predicting response, such complex CLL karyotype relapse after prior chemoimmunotherapy, leaving no good options patients. (Tsimberidou 2006; Rossi 2011; 2014;...
Fosaprepitant (Emend®) is an antiemetic frequently used for the prevention of chemotherapy-induced nausea and vomiting. We previously documented overall 28.7% incidence infusion-site reactions in patients receiving fosaprepitant via peripheral venous access. These data resulted a practice change within our institution; administered more dilute concentrations over 30 min to prevent these adverse events. This retrospective study explored impact this on reactions.Medical records with cancer...
Introduction This study aims to determine the adequacy of current institutional standard practice for CINV prophylaxis EPOCH and R-EPOCH at The Ohio State University James Cancer Hospital. Methods Single-center, retrospective analysis was performed including all patients receiving or chemotherapy Non-Hodgkin’s lymphomas from 1/1/2012 6/30/2017. primary endpoint rate events, which included usage more than 50 percent available doses breakthrough antiemetics while inpatient, hospitalization due...
Introduction: Gemcitabine (G) has single agent activity in T-cell lymphomas (TCL) with response rates >50% the relapsed refractory (RR) setting. Liposomal doxorubicin (LD) TCL both as a and combination, ranging from 40% to 84%. Given safety profile of these agents lack alternative therapies, G plus LD (GLD) was administered patients RR-TCL who were ineligible for clinical trial had no other treatment options. Methods: Patients treated GLD identified retrospectively study inclusion using...